During an interview with The Wall Street Journal earlier this month, Dr. Krishna noted that a common reason projects using IBM Watson AI often unravel is that companies are unprepared for the amount of time and money they must spend just collecting and preparing data. Those unglamorous yet crucial tasks, he said, make up approximately 80 percent of an entire project.
“You run out of patience along the way, because you spend your first year just collecting and cleansing the data,” he said. “And you say, ‘Hey, wait a moment, where’s the AI? I’m not getting the benefit.’ And you kind of bail on it.”
Still, Dr. Krishna maintained that the fairly common occurrence of halted AI projects is “the nature of any early technology.” Even as so many fizzle out, IBM still has about 20,000 more ongoing AI projects, a number that he deemed indicative of overall success.
More articles about AI:
Harvard Business Review: What boards need to know about AI
ZeOmega AI uses social determinants of health to predict risk of opioid abuse
Wearable neurotech companies need to rein in claims, ethics experts say
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
